We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allergan Acne Candidate Meets Endpoints in Phase III Studies
Read MoreHide Full Article
Allergan plc in collaboration with Paratek Pharmaceuticals, Inc. has announced positive results from two phase III studies on sarecycline. The companies are developing sarecycline for the treatment of moderate to severe acne. The companies said the studies met their 12-week primary endpoints.
The efficacy study evaluated sarecycline for the potential treatment of moderate to severe acne in the community setting, which is dosed once daily orally. The drug is a narrow spectrum antibiotic derived from tetracycline.
A look at Allergan’s share price movement over the past six month shows that the stock has outperformed the Zacks classified Medical – Generic Drugs industry. Specifically, Allergan gained 3.7% during this period, while the industry lost 11.7%. Also shares of Paratek closed 9.15% up yesterday.
Coming back to the latest news, SC1401 and SC1402 were double-blinded, placebo-controlled studies, which evaluated the efficacy and safety of treatment with sarecycline compared to placebo in patients with moderate to severe acne, which was the primary endpoint of the study. Results revealed that patients treated with sarecycline (1.5 mg/kg) demonstrated a statistically significant improvement (p < 0.004) compared to placebo across the primary endpoint
Allergan owns the rights for the development and commercialization of sarecycline in the U.S. Based on the positive data, Allergan is planning to file a new drug application (NDA) with the FDA in the second half of this year.
Foamix Pharmaceuticals Ltd. is also conducting a study to evaluate the safety and efficacy of its drug, FMX101, for the treatment of moderate to severe acne.
We remind investors that in order to focus on its branded segment, Allergan sold its generics business to Teva Pharmaceutical Industries Limited (TEVA - Free Report) last year.
Both Allergan and Paratek currently carry a Zacks Rank #3 (Hold).
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Allergan Acne Candidate Meets Endpoints in Phase III Studies
Allergan plc in collaboration with Paratek Pharmaceuticals, Inc. has announced positive results from two phase III studies on sarecycline. The companies are developing sarecycline for the treatment of moderate to severe acne. The companies said the studies met their 12-week primary endpoints.
The efficacy study evaluated sarecycline for the potential treatment of moderate to severe acne in the community setting, which is dosed once daily orally. The drug is a narrow spectrum antibiotic derived from tetracycline.
A look at Allergan’s share price movement over the past six month shows that the stock has outperformed the Zacks classified Medical – Generic Drugs industry. Specifically, Allergan gained 3.7% during this period, while the industry lost 11.7%. Also shares of Paratek closed 9.15% up yesterday.
Coming back to the latest news, SC1401 and SC1402 were double-blinded, placebo-controlled studies, which evaluated the efficacy and safety of treatment with sarecycline compared to placebo in patients with moderate to severe acne, which was the primary endpoint of the study. Results revealed that patients treated with sarecycline (1.5 mg/kg) demonstrated a statistically significant improvement (p < 0.004) compared to placebo across the primary endpoint
Allergan owns the rights for the development and commercialization of sarecycline in the U.S. Based on the positive data, Allergan is planning to file a new drug application (NDA) with the FDA in the second half of this year.
Foamix Pharmaceuticals Ltd. is also conducting a study to evaluate the safety and efficacy of its drug, FMX101, for the treatment of moderate to severe acne.
We remind investors that in order to focus on its branded segment, Allergan sold its generics business to Teva Pharmaceutical Industries Limited (TEVA - Free Report) last year.
Both Allergan and Paratek currently carry a Zacks Rank #3 (Hold).
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>